EPISODE · Dec 8, 2025 · 15 MIN
Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH
from BiotechTV - News · host BiotechTV
She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.
Embed this episode
NOW PLAYING
Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH
0:00
15:36
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 15 minutes long.
When was this BiotechTV - News episode published?
This episode was published on December 8, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!